GlassScriptPhysician profile
Mary Whitaker
NPI 1467482067
$2,691.62
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $255 · 2021: $394 · 2022: $526 · 2023: $502 · 2024: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.35 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $518.64 | 2019-2022 | |
| Abbvie INC. | $502.28 | 2019-2023 | Lo Loestrin Fe |
| Pfizer INC. | $259.45 | 2019-2024 | |
| Amgen INC. | $169.02 | 2019-2021 | |
| Astellas Pharma US INC | $161.52 | 2022-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $157.90 | 2022-2024 | |
| Millicent US INC | $143.59 | 2021-2024 | Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $99.40 | 2023-2024 | Myfembree |
| Myriad Women'S Health, INC. | $84.79 | 2023 | Myrisk |
| Duchesnay USA Incorporated | $75.38 | 2019 | |
| Organon LLC | $74.66 | 2021-2024 | |
| Ascend Therapeutics US, LLC | $69.68 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $57.69 | 2019-2021 | |
| Myovant Sciences INC. | $52.99 | 2021-2022 | |
| Evofem Biosciences, INC. | $44.96 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $41.96 | 2022 | |
| Amag Pharmaceuticals, INC. | $38.45 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $20.71 | 2023 | Vivjoa |
| Bayer Healthcare Pharmaceuticals INC. | $19.22 | 2019 | |
| Novum Pharma, LLC | $18.83 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.97 | 2019 | |
| Currax Pharmaceuticals LLC | $16.43 | 2024 | Onzetra Xsail, Contrave |
| Exact Sciences Corporation | $16.35 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $15.02 | 2020 | |
| Exeltis, USA INC. | $14.73 | 2024 | Slynd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Whitaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.